| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.008 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.15 | 0.008 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.092 | 0.009 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.009 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.009 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.15 | 0.01 |